Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-Hepatobiliary
2022-502317-29-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label trial of volrustomig and rilvegostomig in hepatobiliary cancer (HBC), hepatocellular carcinoma (HCC) and biliary cancer (7 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Jul 2023; status: authorised.
02
Drugs
volrustomigrilvegostomig
03
Conditions
hepatobiliary cancer (HBC)hepatocellular carcinoma (HCC)biliary cancer
Beyond the preview
Go deeper on 2022-502317-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502317-29-00.